Bicara Therapeutics (BCAX) Return on Capital Employed (2024 - 2026)

Bicara Therapeutics has reported Return on Capital Employed for 3 years, with the latest figure at 38.43% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1552.0% year-over-year to 38.43%; the trailing twelve-month figure through Mar 2026 stood at 38.43% (down 1552.0% YoY), and the FY2025 full-year result was 35.24%, down 1197.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 38.43%, up from 39.01% in the prior quarter.
• The five-year high for Return on Capital Employed was 16.51% in Q4 2024, with the low at 39.01% in Q4 2025.
• Historically, Return on Capital Employed has averaged 29.6% across 3 years, with a median of 30.37% in 2025.
• Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 2250 bps — and 2026, when it slumped 1552 bps.
• Bicara Therapeutics' Return on Capital Employed stood at 16.51% in 2024, then sank by 136 bps to 39.01% in 2025, then increased by 1 bps to 38.43% in 2026.
• The last three Return on Capital Employed figures came in at 38.43% (Q1 2026), 39.01% (Q4 2025), and 33.75% (Q3 2025), per Business Quant data.